Silence Therapeutics (SLN) Stock Price, News & Analysis

Company Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: $5.44 to $6.11
• 50-Day Range: $2.18 to $5.94
• 52-Week Range: $1.97 to $22.47
• Volume: 213,957 shs
• Average Volume: 303,245 shs
• Market Capitalization: $162.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.83
• Consensus Rating: Moderate Buy

Silence Therapeutics Stock Analysis - MarketRank™

Silence Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 380th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Silence Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Silence Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Silence Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Silence Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Silence Therapeutics is -3.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Silence Therapeutics has a P/B Ratio of 7.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.18% of the float of Silence Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Silence Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Silence Therapeutics has recently decreased by 14.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Silence Therapeutics does not currently pay a dividend.

Dividend Growth

Silence Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.18% of the float of Silence Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Silence Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Silence Therapeutics has recently decreased by 14.97%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.44

News Sentiment

Silence Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Silence Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for SLN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Silence Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Silence Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Silence Therapeutics is held by insiders.

Percentage Held by Institutions

98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SLN Stock Analysis - Frequently Asked Questions

How have SLN shares performed this year?

Silence Therapeutics' stock was trading at $6.88 at the beginning of 2025. Since then, SLN stock has decreased by 20.9% and is now trading at $5.44.
View the best growth stocks for 2025 here.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (NASDAQ:SLN) announced its earnings results on Thursday, May, 8th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.42. The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative trailing twelve-month return on equity of 62.81%.

Who are Silence Therapeutics' major shareholders?

Top institutional investors of Silence Therapeutics include Siren L.L.C. (9.32%), Siren L.L.C. (9.32%), Redmile Group LLC (7.40%) and Nantahala Capital Management LLC (3.48%).

How do I buy shares of Silence Therapeutics?

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Silence Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/07/2025
• Next Earnings (Estimated): 8/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLN
• CIK: 1479615
• Web: www.silence-therapeutics.com
• Phone: 44-0-20-3457-6900
• Fax: N/A
• Employees: 100
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $33.83
• High Stock Price Target: $75.00
• Low Stock Price Target: $3.00
• Potential Upside/Downside: +521.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.82 million
• Net Margins: -342.00%
• Pretax Margin: -413.52%
• Return on Equity: -62.81%
• Return on Assets: -33.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.31
• Quick Ratio: 9.31

Sales & Book Value

• Annual Sales: $27.70 million
• Price / Sales: 5.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 7.66

Miscellaneous

• Outstanding Shares: 29,930,000
• Free Float: N/A
• Market Cap: $162.82 million
• Optionable: Not Optionable
• Beta: 1.41